Table 2.
Participant demographic and clinical characteristics at the baseline visit, by DSP and DNP status.
| Characteristic | All | DSP‐free (0/1 sign) | Mod to severe DSP (≥2 signs) | P | Pain‐free with or without DSP | DNP with or without DSP | P |
|---|---|---|---|---|---|---|---|
| N | 253 | 188 | 65 | 173 | 80 | ||
| Age, years (mean ± SD) | 43.5 ± 8.01 | 41.8 ± 7.33 | 48.4 ± 7.94 | 0.0001 | 42.7 ± 8.02 | 45.2 ± 7.77 | 0.02 |
| Education, years (mean ± SD) | 13.1 ± 2.54 | 13.1 ± 2.62 | 13.4 ± 2.32 | 0.422 | 13.1 ± 2.49 | 13.2 ± 2.68 | 0.79 |
| Female sex, N (%) | 54 (21%) | 38 (20%) | 16 (25%) | 0.46 | 35 (20.2%) | 19 (23.8%) | 0.53 |
| non‐Hispanic white, N (%) | 108 (42%) | 81 (43%) | 38 (59%) | 0.82 | 70 (41%) | 38 (48%) | 0.29 |
| CD4 nadir (cells/μL; median, IQR) | 178 (29, 294) | 185 (40, 313) | 120 (19, 220) | 0.019 | 181 (27, 279) | 150 (41, 298) | 0.93 |
| Current CD4 (median, IQR) | 282 (446, 607) | 452 (279, 641) | 410 (314, 588) | 0.803 | 440 (261, 634) | 446 (336, 592) | 0.28 |
| On ART, N (%) | 191 (75%) | 132 (70.2%) | 58 (89.2%) | 0.001 | 128 (74%) | 63 (78.8%) | 0.41 |
| Virally suppressed | 120 (47.6%) | 80 (42.8%) | 40 (62.5%) | 0.006 | 78 (45.4%) | 42 (53.2%) | 0.25 |
| Cumulative d‐drug years, median (IQR) | 0.049 (0, 36.9) | 0 (0, 34.1) | 14.5 (0, 42.7) | 0.024 | 0 (0, 29.8) | 12.5 (0, 46.2) | 0.03 |
| Body mass index (mean ± SD) | 26.8 ± 5.97 | 26.8 ± 6.13 | 26.9 ± 5.57 | 0.87 | 27.1 ± 6.12 | 25.9 ± 5.33 | 0.15 |
| Employed, N (%) | 72 (28.3%) | 59 (31.4%) | 13 (20.0%) | 0.073 | 54 (31.2%) | 18 (22.5%) | 0.15 |
ART, antiretroviral therapy; DSP, distal sensory polyneuropathy; DNP, distal neuropathic pain. D‐drug, neurotoxic nucleoside antiretroviral – zalcitabine (ddC), didanosine (ddI), or stavudine (d4T).